News | December 16, 2025
Sanofi secures two breakthrough nods in China for rare blood disorders
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Subscribe To Our Newsletter & Stay Updated
